The Experts below are selected from a list of 45 Experts worldwide ranked by ideXlab platform
S Vuopala - One of the best experts on this subject based on the ideXlab platform.
-
Acitretin in the treatment of severe lichen sclerosus et atrophicus of the Vulva: a double-blind, placebo-controlled study.
Journal of the American Academy of Dermatology, 1994Co-Authors: M T Bousema, U Romppanen, J M Geiger, M Baudin, K Vähä-eskeli, J Vartiainen, S VuopalaAbstract:Promising results have been reported from treatment with oral retinoids in patients with severe lichen sclerosus et atrophicus (LSA) of the Vulva. The aim of our study was to determine the efficacy of acitretin (20 to 30 mg/day) for 16 weeks in LSA. Seventy-eight patients were enrolled into a multicenter, randomized, placebo-controlled, double-blind trial. The primary measure of efficacy was the "responder" rate based on the assessment of characteristic clinical features of LSA of the Vulva (Pruritus, burning, atrophy, hyperkeratosis, and secondary features such as erosions, ulcers, edema, or lichenification) and on the extent of the lesions. From the 46 patients eligible for efficacy analysis, a significantly higher number of responders was observed in the acitretin-treatment group (14 of 22 patients) as compared with the placebo-treatment group (6 of 24 patients). Typical retinoid adverse reactions were observed in all patients receiving active drug. Acitretin is effective in treating women with severe LSA of the Vulva.
Vuopala S - One of the best experts on this subject based on the ideXlab platform.
-
Acitretin in the treatment of severe lichen sclerosus et atrophicus of the Vulva: A double-blind, placebo-controlled study
Journal of The American Academy of Dermatology, 1994Co-Authors: Bousema Mt, Romppanen U, Geiger Jm, Baudin M, Vähä-eskeli K, Vartiainen J, Vuopala SAbstract:Background: Promising results have been reported from treatment with oral retinoids in patients with severe lichen sclerosus et atrophicus (LSA) of the Vulva. Objective: The aim of our study was to determine the efficacy of acitretin (20 to 30 mg/day) for 16 weeks in LSA. Methods: Seventy-eight patients were enrolled into a multicenter, randomized, placebo-controlled, double-blind trial. The primary measure of efficacy was the "responder" rate based on the assessment of characteristic clinical features of LSA of the Vulva (Pruritus, burning, atrophy, hyperkeratosis, and secondary features such as erosions, ulcers, edema, or lichenification) and on the extent of the lesions. Results: From the 46 patients eligible for efficacy analysis, a significantly higher number of responders was observed in the acitretin-treatment group (14 of 22 patients) as compared with the placebo-treatment group (6 of 24 patients). Typical retinoid adverse reactions were observed in all patients receiving active drug. Conclusion: Acitretin is effective in treating women with severe LSA of the Vulva.
Fu Bing - One of the best experts on this subject based on the ideXlab platform.
-
Clinical study of point-injection medicine in the treatment of white lesions of the Vulva
China Medical Herald, 2020Co-Authors: Fu BingAbstract:Objective:To investigate the curative effect of point-injection medicine in the treatment of the patients with white lesions of Vulva (WLV). Methods: 168 patients with WLV were treated with point-injection medicine. Five acupotints, Qihai, Ququan (bilateral), Xuehai (bilateral), Qixue and Zusanli (bilateral) were selected and used in turn. Each time three acupoints were chosen and injected with the mixture of placenta tissue fluid and VitB12. During the treatment and after the treatment, the local changes, signs and pathological changes of the patients were observed and the curative effect was evaluated. Results: After point-injection treatment, the symptom of Vulva Pruritus of the patients was basically remitted or disappeared; the morphology and colourand luster of Vulva of the patients basically reached normal levels. Total effective rate was 100%; total effective rate was 84.5%. Conclusion: Point-injection is an effective method in the treatment of the patients with white lesions of Vulva.
Long Yu-tong - One of the best experts on this subject based on the ideXlab platform.
-
Clinical Observation of Point-injection Medicine in Treatment of White Lesions of the Vulva:a report of 24 cases
Progress in Modern Biomedicine, 2020Co-Authors: Long Yu-tongAbstract:Objective:To investigate the curative effect of point-injection medicine in the treatment of the padents with white lesions of Vulva(WLV).Methods:24 patients with WLV were treated with point-injection medicine.Five acupoints, Qhai,Ququan(bilateral),Xuehai(bilateral),Qixue and Zusanli(bilateral),were selected and used in turn.Each time three acupoints were chosen and injected with the mixture of placenta tissue fluid and Vit B12.During and after treatment,the local changes,signs and pathological changes of the patients were observed and the curative effect was evaluated.Results:After point- injection treatment,the symptom of Vulva Pruritus of the patients was basically remitted or disappeared; the morphology and colour and luster of Vulva of the patients basically reached normal levels.Total effective rate was 100%; total effectual rate was 87.5%. Conclusion:Point-injection ia an effective method in the treatment of the patients with white lesions of Vulva.
M T Bousema - One of the best experts on this subject based on the ideXlab platform.
-
Acitretin in the treatment of severe lichen sclerosus et atrophicus of the Vulva: a double-blind, placebo-controlled study.
Journal of the American Academy of Dermatology, 1994Co-Authors: M T Bousema, U Romppanen, J M Geiger, M Baudin, K Vähä-eskeli, J Vartiainen, S VuopalaAbstract:Promising results have been reported from treatment with oral retinoids in patients with severe lichen sclerosus et atrophicus (LSA) of the Vulva. The aim of our study was to determine the efficacy of acitretin (20 to 30 mg/day) for 16 weeks in LSA. Seventy-eight patients were enrolled into a multicenter, randomized, placebo-controlled, double-blind trial. The primary measure of efficacy was the "responder" rate based on the assessment of characteristic clinical features of LSA of the Vulva (Pruritus, burning, atrophy, hyperkeratosis, and secondary features such as erosions, ulcers, edema, or lichenification) and on the extent of the lesions. From the 46 patients eligible for efficacy analysis, a significantly higher number of responders was observed in the acitretin-treatment group (14 of 22 patients) as compared with the placebo-treatment group (6 of 24 patients). Typical retinoid adverse reactions were observed in all patients receiving active drug. Acitretin is effective in treating women with severe LSA of the Vulva.
